Search

Displaying results 4801 - 4810 of 10000 in total
  1. Drug

    Cetilistat

    go.drugbank.com/drugs/DB06586
    Investigational

    Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

  2. Drug

    Piperacetazine

    go.drugbank.com/drugs/DB06808
    ApprovedVet approvedWithdrawn

    Piperacetazine was an antipsychotic.

  3. Drug

    SGX-523

    go.drugbank.com/drugs/DB06314
    Investigational

    A MET receptor tyrosine kinase inhibitor.

  4. Drug

    Livmoniplimab

    go.drugbank.com/drugs/DB18939
    Investigational

    Livmoniplimab is under investigation in clinical trial NCT06109272 (A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination … With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)).

  5. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

  6. Drug

    Venglustat

    go.drugbank.com/drugs/DB14966
    Investigational

    Venglustat is under investigation in clinical trial NCT01674036 (Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men).

  7. Drug

    Carfentanil

    go.drugbank.com/drugs/DB01535
    IllicitInvestigationalVet approved

    Carfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen. … Carfentanil is intended for large-animal use only as its extreme potency makes it inappropriate for use in humans.

  8. Drug

    OPC-28326

    go.drugbank.com/drugs/DB05461
    Experimental

    It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

  9. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

  10. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.